<DOC>
	<DOCNO>NCT02697188</DOCNO>
	<brief_summary>Determine serum pharmacokinetic profile two oral formulation T-esters ( one TE one TU ) administer - ( QD ) twice-daily ( BID ) hypogonadal men .</brief_summary>
	<brief_title>Pilot Pharmacokinetic Study Oral Testosterone Ester Formulations Hypogonadal Men</brief_title>
	<detailed_description>Five period cross-over study subject receive single day dose period . Dosing either QD BID one two T ester ( T-enanthate ( TE ) T-undecanoate ( TU ) ) . Dosing within 5 minute meal ( breakfast BID dose dinner ) . There minimum 5-day washout period . Subjects hypogonadal men .</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Male , age 18 65 Serum total testosterone less equal 250 ng/dL Naive androgen replacement therapy Subject must stable dos thyroid adrenal replacement hormone least 14 day prior enrollment Significant intercurrent disease type , particular , liver , kidney heart disease , uncontrolled diabetes mellitus psychiatric illness . Patients treat hyperlipidemia exclude provide stable lipidlowering mediation least three month . For noninsulin dependent diabetic subject , HbA1c &gt; 9 % . Abnormal prostate digital rectal examination , elevate PSA ( serum PSA &gt; 4ng/mL ) , AUA Sympton Score great equal 15 point , history prostate cancer . Serum transaminases &gt; 2X upper limit normal ( ULN ) serum bilirubin &gt; 2.0 mg/dL . History severe multiple allergy , severe adverse drug reaction leucopenia . Known hypersensitivity lidocaine surgical dressing . History abnormal bleeding tendency . Oral , topical , buccal T therapy within previous week , intramuscular T injection within previous 4 week . Use dietary supplement may increase serum T , androstenedione DHEA , within previous 4 week . Know malabsorption syndrome and/or current treatment oral lipase inhibitor , bile acidbinding resin , colestipol , fibric acid derivative , gemfibrozil , probucol . Smokers unable refrain smoke confinement period . History , current evidence , abuse alcohol drug substance . Poor compliers unlikely attend . Receipt drug part research study within 30 day inital dose administration study . Blood donation ( usually 550 mL ) within 12week period initial study dose . Hematocrit le 35 % . Known clinical polycythemia hematocrit great 50 % . Current use paroxetine clomipramine , antiandrogens , estrogen , p450 enzyme inducer , barbiturate . History sleep apnea .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>testosterone</keyword>
	<keyword>male hypogonadism</keyword>
	<keyword>low testosterone</keyword>
</DOC>